BACKGROUND Colon cancer(CC)occurrence and progression are considerably influenced by the tumor microenvironment.However,the exact underlying regulatory mechanisms remain unclear.AIM To investigate immune infiltration-...BACKGROUND Colon cancer(CC)occurrence and progression are considerably influenced by the tumor microenvironment.However,the exact underlying regulatory mechanisms remain unclear.AIM To investigate immune infiltration-related differentially expressed genes(DEGs)in CC and specifically explored the role and potential molecular mechanisms of complement factor I(CFI).METHODS Immune infiltration-associated DEGs were screened for CC using bioinformatics.Quantitative reverse transcription polymerase chain reaction was used to examine hub DEGs expression in the CC cell lines.Stable CFI-knockdown HT29 and HCT116 cell lines were constructed,and the diverse roles of CFI in vitro were assessed using CCK-8,5-ethynyl-2’-deoxyuridine,wound healing,and transwell assays.Hematoxylin and eosin staining and immunohistochemistry staining were employed to evaluate the influence of CFI on the tumorigenesis of CC xenograft models constructed using BALB/c male nude mice.Key proteins associated with glycolysis and the Wnt pathway were measured using western blotting.RESULTS Six key immune infiltration-related DEGs were screened,among which the expression of CFI,complement factor B,lymphoid enhancer binding factor 1,and SRY-related high-mobility-group box 4 was upregulated,whereas that of fatty acid-binding protein 1,and bone morphogenic protein-2 was downregulated.Furthermore,CFI could be used as a diagnostic biomarker for CC.Functionally,CFI silencing inhibited CC cell proliferation,migration,invasion,and tumor growth.Mechanistically,CFI knockdown downregulated the expression of key glycolysis-related proteins(glucose transporter type 1,hexokinase 2,lactate dehydrogenase A,and pyruvate kinase M2)and the Wnt pathway-related proteins(β-catenin and c-Myc).Further investigation indicated that CFI knockdown inhibited glycolysis in CC by blocking the Wnt/β-catenin/c-Myc pathway.CONCLUSION The findings of the present study demonstrate that CFI plays a crucial role in CC development by influencing glycolysis and the Wnt/β-catenin/c-Myc pathway,indicating that it could serve as a promising target for therapeutic intervention in CC.展开更多
目的 探讨骨肉瘤化疗耐药中FoxM1与c-myc的关系及其作用机制。方法 在骨肉瘤亲本细胞(HOS、U2OS)、筛选稳定顺铂耐药细胞(HOS/R、U2OS/R)、慢病毒转染稳定FoxM1过表达细胞株(HOS/FoxM1、U2OS/FoxM1)及空载体对照(HOS/NC、U2OS/NC)中,采...目的 探讨骨肉瘤化疗耐药中FoxM1与c-myc的关系及其作用机制。方法 在骨肉瘤亲本细胞(HOS、U2OS)、筛选稳定顺铂耐药细胞(HOS/R、U2OS/R)、慢病毒转染稳定FoxM1过表达细胞株(HOS/FoxM1、U2OS/FoxM1)及空载体对照(HOS/NC、U2OS/NC)中,采用Western blot法检测FoxM1和c-myc蛋白的表达。应用CCK-8细胞增殖实验检测FoxM1抑制剂RCM-1对骨肉瘤细胞顺铂敏感性的影响;采用生物信息学方法分析FoxM1和c-myc表达与患者预后的关系。结果 FoxM1和c-myc在骨肉瘤顺铂耐药细胞中的蛋白表达比亲本细胞明显升高。与空载体对照组中FoxM1(0.26±0.03 vs 0.37±0.02)、c-myc(0.35±0.07 vs 0.59±0.03)相比,FoxM1过表达细胞中FoxM1(0.81±0.13 vs 0.61±0.01)和c-myc(1.19±0.08 vs 1.61±0.13)蛋白表达升高,差异均有统计学意义(P<0.05)。采用10μmol/L FoxM1抑制剂RCM-1处理后,顺铂耐药细胞(FoxM1:0.23±0.01 vs 0.19±0.02,c-myc:0.39±0.01 vs 0.31±0.04)和FoxM1过表达细胞中(FoxM1:0.11±0.03 vs 0.10±0.02,c-myc:0.35±0.01 vs 0.36±0.02)FoxM1和c-myc蛋白表达均明显下降。与单独顺铂给药组相比,采用顺铂联合FoxM1抑制剂RCM-1处理,骨肉瘤耐药细胞和FoxM1过表达细胞的增殖能力均降低,差异均有统计学意义(P<0.05)。生物信息学分析发现:FoxM1和c-myc高表达组患者的总生存期低于低表达组(P<0.05)。结论 FoxM1可能通过上调c-myc表达促进骨肉瘤细胞对顺铂耐药,联合运用FoxM1抑制剂能够增强骨肉瘤耐药细胞对化疗的敏感性,了解其分子机制有望为临床逆转骨肉瘤化疗耐药提供新的治疗靶点。展开更多
文摘BACKGROUND Colon cancer(CC)occurrence and progression are considerably influenced by the tumor microenvironment.However,the exact underlying regulatory mechanisms remain unclear.AIM To investigate immune infiltration-related differentially expressed genes(DEGs)in CC and specifically explored the role and potential molecular mechanisms of complement factor I(CFI).METHODS Immune infiltration-associated DEGs were screened for CC using bioinformatics.Quantitative reverse transcription polymerase chain reaction was used to examine hub DEGs expression in the CC cell lines.Stable CFI-knockdown HT29 and HCT116 cell lines were constructed,and the diverse roles of CFI in vitro were assessed using CCK-8,5-ethynyl-2’-deoxyuridine,wound healing,and transwell assays.Hematoxylin and eosin staining and immunohistochemistry staining were employed to evaluate the influence of CFI on the tumorigenesis of CC xenograft models constructed using BALB/c male nude mice.Key proteins associated with glycolysis and the Wnt pathway were measured using western blotting.RESULTS Six key immune infiltration-related DEGs were screened,among which the expression of CFI,complement factor B,lymphoid enhancer binding factor 1,and SRY-related high-mobility-group box 4 was upregulated,whereas that of fatty acid-binding protein 1,and bone morphogenic protein-2 was downregulated.Furthermore,CFI could be used as a diagnostic biomarker for CC.Functionally,CFI silencing inhibited CC cell proliferation,migration,invasion,and tumor growth.Mechanistically,CFI knockdown downregulated the expression of key glycolysis-related proteins(glucose transporter type 1,hexokinase 2,lactate dehydrogenase A,and pyruvate kinase M2)and the Wnt pathway-related proteins(β-catenin and c-Myc).Further investigation indicated that CFI knockdown inhibited glycolysis in CC by blocking the Wnt/β-catenin/c-Myc pathway.CONCLUSION The findings of the present study demonstrate that CFI plays a crucial role in CC development by influencing glycolysis and the Wnt/β-catenin/c-Myc pathway,indicating that it could serve as a promising target for therapeutic intervention in CC.
文摘目的 探讨骨肉瘤化疗耐药中FoxM1与c-myc的关系及其作用机制。方法 在骨肉瘤亲本细胞(HOS、U2OS)、筛选稳定顺铂耐药细胞(HOS/R、U2OS/R)、慢病毒转染稳定FoxM1过表达细胞株(HOS/FoxM1、U2OS/FoxM1)及空载体对照(HOS/NC、U2OS/NC)中,采用Western blot法检测FoxM1和c-myc蛋白的表达。应用CCK-8细胞增殖实验检测FoxM1抑制剂RCM-1对骨肉瘤细胞顺铂敏感性的影响;采用生物信息学方法分析FoxM1和c-myc表达与患者预后的关系。结果 FoxM1和c-myc在骨肉瘤顺铂耐药细胞中的蛋白表达比亲本细胞明显升高。与空载体对照组中FoxM1(0.26±0.03 vs 0.37±0.02)、c-myc(0.35±0.07 vs 0.59±0.03)相比,FoxM1过表达细胞中FoxM1(0.81±0.13 vs 0.61±0.01)和c-myc(1.19±0.08 vs 1.61±0.13)蛋白表达升高,差异均有统计学意义(P<0.05)。采用10μmol/L FoxM1抑制剂RCM-1处理后,顺铂耐药细胞(FoxM1:0.23±0.01 vs 0.19±0.02,c-myc:0.39±0.01 vs 0.31±0.04)和FoxM1过表达细胞中(FoxM1:0.11±0.03 vs 0.10±0.02,c-myc:0.35±0.01 vs 0.36±0.02)FoxM1和c-myc蛋白表达均明显下降。与单独顺铂给药组相比,采用顺铂联合FoxM1抑制剂RCM-1处理,骨肉瘤耐药细胞和FoxM1过表达细胞的增殖能力均降低,差异均有统计学意义(P<0.05)。生物信息学分析发现:FoxM1和c-myc高表达组患者的总生存期低于低表达组(P<0.05)。结论 FoxM1可能通过上调c-myc表达促进骨肉瘤细胞对顺铂耐药,联合运用FoxM1抑制剂能够增强骨肉瘤耐药细胞对化疗的敏感性,了解其分子机制有望为临床逆转骨肉瘤化疗耐药提供新的治疗靶点。